| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | HAE | Common Stock | Sale | -$77.9K | -822 | -4.79% | $94.82 | 16.4K | May 17, 2024 | Direct | F1, F2 |
| transaction | HAE | Common Stock | Tax liability | -$30.6K | -320 | -1.96% | $95.73 | 16K | May 17, 2024 | Direct | F2, F3 |
| transaction | HAE | Common Stock | Award | +6.27K | +39.1% | 22.3K | May 17, 2024 | Direct | F2, F4, F5 | ||
| transaction | HAE | Common Stock | Sale | -$93.8K | -987 | -4.43% | $95.08 | 21.3K | May 20, 2024 | Direct | F1, F2 |
Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.
Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).
| Id | Content |
|---|---|
| F1 | Transaction pursuant to an existing 10b5-1 trading plan dated August 28, 2023 (fully executed as of August 31, 2023). |
| F2 | This number includes unvested restricted stock units ("RSUs") previously reported. |
| F3 | Represents shares withheld for tax obligations in connection with the vesting of certain RSUs previously reported in Table I. |
| F4 | The securities awarded are in the form of RSUs issued pursuant to the Haemonetics Corporation Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% on the first anniversary of the date of grant. |
| F5 | Each RSU represents a contingent right to receive one (1) share of the Issuer's common stock when vested. |